Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Investigating The Cardioprotective Effects of Growth Differentiation Factor 15 in Diabetic Cardiomyopathy
FY 2023-24
Summary
New Protein Therapies for Diabetic Heart Disease
It is now estimated that over 450 million people have type 2 diabetes (T2D), many of whom are also obese. The obesity epidemic is now recognized as a major public health concern because it is considered a major risk factor for the development of many chronic diseases, including T2D and heart disease. Of interest, a protein known as GDF15 is being investigated as a weight loss drug for T2D, as it can also lower blood sugar. However, all new drugs being pursued for the treatment of T2D must also undergo studies on how they affect the heart, since heart disease represents the number 1 cause of death for these individuals. In particular, people with T2D often have diabetic heart disease where their heart cannot relax as well between each pump. Our research has shown that GDF15 treatment improves diabetic heart disease in a mouse model of T2D independent of its weight loss effects. However, we have limited information regarding how GDF15 is able to improve heart function. Thus, we aim to identify how GDF15 is beneficial in the context of diabetic heart disease. Using computer modelling, we discovered that GDF15 could bind to a protein called toll-like receptor 2 (TLR2) which normally causes inflammation. We thus hypothesize that GDF15 could decrease inflammation in the heart by inhibiting TLR2. If correct, our research will not only progress GDF15 as a potential medication for T2D and diabetic heart disease, but also opens the door for its application in other inflammation-related diseases.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506351
Name
Mangra-Bala Indiresh
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating The Cardioprotective Effects of Growth Differentiation Factor 15 in Diabetic Cardiomyopathy
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Diabetes; Diabetic Cardiomyopathy; Gdf15
Abstract
New Protein Therapies for Diabetic Heart Disease
It is now estimated that over 450 million people have type 2 diabetes (T2D), many of whom are also obese. The obesity epidemic is now recognized as a major public health concern because it is considered a major risk factor for the development of many chronic diseases, including T2D and heart disease. Of interest, a protein known as GDF15 is being investigated as a weight loss drug for T2D, as it can also lower blood sugar. However, all new drugs being pursued for the treatment of T2D must also undergo studies on how they affect the heart, since heart disease represents the number 1 cause of death for these individuals. In particular, people with T2D often have diabetic heart disease where their heart cannot relax as well between each pump. Our research has shown that GDF15 treatment improves diabetic heart disease in a mouse model of T2D independent of its weight loss effects. However, we have limited information regarding how GDF15 is able to improve heart function. Thus, we aim to identify how GDF15 is beneficial in the context of diabetic heart disease. Using computer modelling, we discovered that GDF15 could bind to a protein called toll-like receptor 2 (TLR2) which normally causes inflammation. We thus hypothesize that GDF15 could decrease inflammation in the heart by inhibiting TLR2. If correct, our research will not only progress GDF15 as a potential medication for T2D and diabetic heart disease, but also opens the door for its application in other inflammation-related diseases.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mangra-Bala, Indiresh
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~